Polypeptide-Drug Conjugates for Oncology (OncoPDCs)

Self-assembling OncoPDCs represent a new platform of cancer treatment modality, consisting of intrinsically disordered domains, cancer cell receptor-binding sequences, and biologically active agents. These OncoPDCs are designed for direct implantation into hard-to-reach solid tumors, such as those found in the brain and pancreas, using image-guided convection-enhanced delivery (CED) and percutaneous injection, respectively. By concentrating cytotoxic or immune-modulating payloads within tumor tissues and ancer cells, OncoPDCs enable targeted, localized, and prolonged drug release at the tumor site, optimizing therapeutic outcomes while minimizing side effects.